Interpace Biosciences, Inc. — Revenue by Fiscal Year
16 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/9eaaa898-944d-4962-9962-52dc310bdc0b/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $38.7M | 2025-01-01 – 2025-12-31 | evidence 0001493152-26-013646 |
| FY 2024 | $46.9M | 2024-01-01 – 2024-12-31 | evidence 0001641172-25-001686 |
| FY 2023 | $40.0M | 2023-01-01 – 2023-12-31 | evidence 0001641172-25-001686 |
| FY 2022 | $31.8M | 2022-01-01 – 2022-12-31 | evidence 0001493152-23-009106 |
| FY 2021 | $33.1M | 2021-01-01 – 2021-12-31 | evidence 0001493152-23-009106 |
| FY 2020 | $32.4M | 2020-01-01 – 2020-12-31 | evidence 0001493152-21-007629 |
| FY 2019 | $24.2M | 2019-01-01 – 2019-12-31 | evidence 0001493152-21-001330 |
| FY 2018 | $21.9M | 2018-01-01 – 2018-12-31 | evidence 0001493152-19-003733 |
| FY 2017 | $15.9M | 2017-01-01 – 2017-12-31 | evidence 0001493152-19-003733 |
| FY 2016 | $13.1M | 2016-01-01 – 2016-12-31 | evidence 0001437749-17-005779 |
| FY 2015 | $9.4M | 2015-01-01 – 2015-12-31 | evidence 0001054102-16-000097 |
| FY 2014 | $1.5M | 2014-01-01 – 2014-12-31 | evidence 0001054102-16-000097 |
| FY 2013 | $146.5M | 2013-01-01 – 2013-12-31 | evidence 0001054102-15-000012 |
| FY 2012 | $126.9M | 2012-01-01 – 2012-12-31 | evidence 0001054102-13-000005 |
| FY 2011 | $157.3M | 2011-01-01 – 2011-12-31 | evidence 0001054102-12-000008 |
| FY 2010 | $134.6M | 2010-01-01 – 2010-12-31 | evidence 0001054102-12-000008 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Interpace Biosciences, Inc. — all facts · Net Income · Operating Income